SCHEMBL20148034

SCHEMBL20148034

CCN1CCC(C)(C(=O)Nc2cc(F)ccc2C)CC1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
CETP P11597 2/20 0.45
ALDH1A1 P00352 3/20 0.44
TSHR P16473 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
RET P07949 1/20 0.43
TP53 P04637 1/20 0.42
ABL1 P00519 2/20 0.42
HSD11B1 P28845 1/20 0.42
SSTR5 P35346 1/20 0.41
MAPT P10636 1/20 0.41
MAPK1 P28482 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20158644 0.86 CETP (0.47) POLBMEN1KMT2ACETPALDH1A1
SCHEMBL25504631 0.85 CETP (0.46) MEN1KMT2ACETPALDH1A1TSHR
SCHEMBL20158641 0.83 CETP (0.45) MEN1KMT2ACETPALDH1A1TSHR
SCHEMBL28687087 0.78 NTRK1 (0.52) MEN1KMT2ACETPALDH1A1TSHR
SCHEMBL30273016 0.78 NTRK1 (0.52) MEN1KMT2ACETPALDH1A1TSHR
SCHEMBL26050285 0.74 NPC1 (0.49) POLBMEN1KMT2AALDH1A1TP53
SCHEMBL21651991 0.73 CCR3 (0.49) RET
SCHEMBL21651967 0.72 DRD2 (0.60) POLBMEN1KMT2ATSHRTP53
SCHEMBL4819221 0.72 MAPK1 (0.55) MEN1KMT2AALDH1A1TSHRMAPT
SCHEMBL4819210 0.72 MAPK1 (0.55) MEN1KMT2AALDH1A1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2019-10-15 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10441581-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 POLB 3354/4885MEN1 653/4885KMT2A 1112/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 POLB 3354/4885MEN1 653/4885KMT2A 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.